Dystonia with marked diurnal variation associated with biopterin deficiency

Neurology

Volumn 38, Issue 5, 1988, Pages 707-711

  Fink, J K ^a   Barton, N ^a   Cohen, W ^d   Lovenberg, W ^b   Burns, R S ^c   Hallett, M ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Merrill Dow Research Institute ^*  (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOPTERIN; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; CASE REPORT; CHILD; CIRCADIAN RHYTHM; DYSTONIA; FEMALE; HEREDITY; HUMAN; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; BIOPTERIN; CARBIDOPA; CASE REPORT; CHILD; CHILD, PRESCHOOL; CIRCADIAN RHYTHM; DRUG COMBINATIONS; DYSTONIA; FEMALE; HOMOVANILLIC ACID; HUMAN; HYDROXYINDOLEACETIC ACID; LEVODOPA; MALE; NEOPTERIN; SIBLING RELATIONS;

EID: 0023914805     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/wnl.38.5.707     Document Type: Article

References (34)

1. Marsden CD. The pathophysiology of movement disorders. Neurol Clin 1981;2:435–460.
2. Carpenter MB, Sutin J. Human neuroanatomy, 7th ed. Baltimore: Williams & Wilkins, 1983:609.
3. Hornykiewicz O, Kish SJ, Becker LE, Farley I, Shannak K. Brain neurotransmitters in dystonia musculorum deformans. N Engl J Med 1986;315:347–353.
4. Ayd F. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054–1064.
5. Henderson VW, Wooten GF. Neuroleptic malignant syndrome: a pathogenetic role for dopamine receptor blockade. Neurology 1981;31:132–137.
6. Lang AE. Dopamine agonists in the treatment of dystonia. Clin Neuropharmacol 1985;8:38–57.
7. Barrett RE, Yahr MD, Duvoisin RC. Torsion dystonia and spasmodic torticollis: results of treatment with L-dopa. Neurology 1970;20:122–130.
8. Chase TN. Biochemical and pharmacologic studies of dystonia. Neurology 1970;20:107–113.
9. Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol 1988;50:377–384.
10. Deonna T. Dopa-sensitive progressive dystonia of childhood with fluctuations of symptoms: Segawa’ s syndrome and possible variants. Neuropediatrics 1986;17:81–85.
11. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976;14:215–233.
12. Kaufman S, Berlow S, Summer GK, et al. Hyperphenylalanemia due to a deficiency of biopterin: a variant form of phenylketonuria. N Engl J Med 1978;299:673–679.
13. LeWitt PA, Miller LP, Levine RA, et al. Tetrahydrobiopterin in dystonia: identification of abnormal metabolism and therapeutic trials. Neurology 1986;36:760–764.
14. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IW. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983;80:4546–4550.
15. Fahn S. Torsion dystonia: clinical spectrum and treatment. Semin Neurol 1982;2:316–323.
16. Deonna T, Ferreira A. Idiopathic fluctuating dystonia: a case of foot dystonia and writer’ s cramp responsive to L-dopa. Dev Med Child Neurol 1985;27:814–821.
17. Gordon N. Fluctuating dystonia and allied syndromes. Neuropediatrics 1982;13:152–154.
18. Agrawal R, Bagga A, Kaira V. Progressive dystonia with marked diurnal variation. Indian J Pediatr 1984;51:747–749.
19. Ouvrier RA. Progressive dystonia with marked diurnal variation. Ann Neurol 1978;4:412–417.
20. Chan-Lui WY, Low LCK. Progressive dystonia with marked diurnal fluctuation in a Chinese family. Aust Paediatr J 1984;20:143–146.
21. Bertelsmann FW, Smit LME. Progressive dystonia with marked diurnal fluctuation. Clin Neurol Neurosurg 1985;87:123–126.
22. Williams AC, Levine RA, Chase TN, Lovenberg W, Calne DB. CSF hydroxylase cofactor levels in some neurological diseases. J Neurol Neurosurg Psychiatry 1980;43:735–738.
23. Cooper JR, Bloom FE, Roth RH. Catecholamines. I. General aspects. In: The biochemical basis of neuropharmacology, 4th ed. New York: Oxford University Prew, 1982:129–131.
24. Levine R, Miller L, Lovenberg W. Tetrahydrobiopterin in the striatum: localization in dopamine nerve terminals and role in catecholamine synthesis. Science 1981;214:919–921.
25. Brenneman A, Kaufman S. The role of tetrahydropteridinea in the enzymatic conversion of tyrosine to 3,4-dihydroxyphenylalanine. Biochem Biophys Res Commun 1964;17:177–183.
26. Lewitt P, Miller L, Newman R, et al. Tyrosine hydroxylase cofactor (tetrahydrobiopterin) in parkinsonism. Adv Neurol 1984;40:459–462.
27. Lovenberg W, Levine R, Aiken M, Miller L, LeWitt P. Regulation of biogenic amine synthesis by the hydroxylase cofactor and its relation to aging and parkinsonism. In: Regelson G, Sinex F, eds. Intervention in the aging process, part A. Quantitation, epidemiology, and clinical research. New York: Alan R Liss, 1983:215–224.
28. Levine R, Kuhn D, Lovenberg W. Regional distribution of hydrorylase cofactor in rat brain. J Neurochem 1979;32:1575–1578.
29. Endres W, Niederwieser A, Curtius H, Wang M, Ohrt B, Scheub J. Atypical phenylketonuria due to biopterin deficiency. Helv Paediatr Acta 1982;37:489–498.
30. Hoganson G, Berlow S, Kaufman S, et al. Biopterin synthesis defects: problem in diagnosis. Pediatrics 1984;74:1004–1011.
31. Tanaka K, Yoneda M, Nakajima T, Miyatake T, Owada M. Dihydrobiopterin synthesis defect an adult with diurnal fluctuation of symptoms. Neurology 1987;37:519–522.
32. Dhont J. Tetrahydrobiopterin deficiencies: preliminary analysis from an international survey. J Pediatr 1984;104:501–508.
33. Langlais P, Walsh FX, Bird ED, Levy HL. Cerebrospinal fluid neurotransmitter metabolites in neurologically normal infants and children. Pediatrics 1985;75:580–586.
34. Seifert WE Jr, Foxx JL, Butler IJ. Age effect on dopamine and serotonin metabolite levels in cerebrospinal fluid. Ann Neurol 1980;8:38–42.